According to the report, the size of Asia Pacific Blood Testing Market size is valued at USD 10 billion in 2020. This value is forecasted to be growing at a CAGR of 3.35% to reach USD 11.79 billion by 2025.
The blood testing market involves blood sampling and collection activities. Blood testing helps doctors to identify, detect any underlying issues in the body through blood tests. HIV/AIDS, Diabetes, Cancers, and any other Heart issues can be detected through blood tests.
Key factors contributing to the growth of this market contain the growing number of chronic cases and the high price of treatment, rise in occurrence of infectious diseases, speedily increasing aging population, boost in product approvals and launches, increase in demand for quick diagnostic techniques, and high commonness of bloodstream infections.
The Asia Pacific has reported as fastest growing market for Blood testing. The dense population in this region drives the market growth. The demand for frequent check-ups for increasing diseases such as Diabetes, Cancers, Liver Diseases, and Cardiovascular disorders increases market size. The government schemes in this region on creating awareness of medications, blood donation drives, and personalizing medications depending on body type are a boom to market.
During the forthcoming years, Asia-Pacific has been recognized as the fastest-growing region. Blood is a vital component of the body and is used routinely in a wide range of hospital procedures. Every year, millions of blood units are donated globally and used in necessary transplantation, cancer therapies, and accident victims and for patients undergoing other forms of surgeries.
Still, factor such as lack of technically skilled professionals is restraining the growth of this market.
This research report on the Asia Pacific Blood Testing Market has been segmented and sub-segmented into the following categories:
By Type:
By Disease:
By Method:
By Country:
Based on the region, China and India are the fastest-growing markets in the Asia-Pacific region. China and Japan are highly populated regions, and hence the spread of infectious diseases is on the rise every year, notably. The regulations and strict guidelines are made by the corresponding government to regulate and prevent infections. 47% of the Asia Pacific population is reported to donate blood in recent years. As the hike is seen in blood donation and drives, blood collection and sampling are also observed. India holds the largest share for blood banks, helping hospitals and clinics provide blood in emergency cases. Growing major vital players across the Asia Pacific region also leads the market level to rise.
Companies dominating the Asia Pacific Blood Testing Market Profiled in the Report are Bio-Rad Laboratories Inc. (U.S.), Siemens Healthcare (Germany), Grifols (Spain), Nanosphere Inc. (U.S.), BioMérieux (France), Dickinson and Company (U.S.), Ortho Clinical Diagnostics Inc. (U.S.), Roche Diagnostics (Switzerland), Alere Inc. (U.S.), Bruker Corporation (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.) and Beckman Coulter (U.S.).
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Complete Blood Count
5.1.1.1 Red Blood Cells
5.1.1.2 White Blood Cells
5.1.1.3 Haemoglobin
5.1.1.4 Hematocrit
5.1.1.5 Platelets
5.1.2 Blood Chemistry Tests
5.1.2.1 Test for Electrolytes
5.1.2.2 Blood Glucose
5.1.2.3 Calcium
5.1.2.4 Test for Kidney Function
5.1.3 Blood Enzyme Tests
5.1.3.1 Troponin
5.1.3.2 Creatine Kinase
5.1.4 Blood Clotting Tests
5.1.4.1 Prothrombin time
5.1.4.2 Activated Partial Thromboplastin time
5.1.4.3 Blood Coagulation
5.2 By Diseases
5.2.1 Anaemia
5.2.2 Infection
5.2.3 Leukaemia
5.2.4 Hypokalemia
5.2.5 Kidney Disorders
5.2.6 Heart Attack
5.2.7 Coronary Heart Disease
5.3 By Methods
5.3.1 Manual Blood Culture Testing
5.3.2 Automated Blood Culture Testing
5.3.2.1 Automated Blood Culture System
5.3.2.2 Blood Culture Instruments
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Bio-Rad Laboratories Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Siemens Healthcare
8.3 Grifols
8.4 Nanosphere Inc.
8.5 BioMérieux
8.6 Dickinson and Company
8.7 Ortho Clinical Diagnostics Inc.
8.8 Roche Diagnostics
8.9 Alere Inc.
8.10 Bruker Corporation
8.11 Abbott Laboratories
8.12 Thermo Fisher Scientific Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
